Table 2.

Genetic variants of L.R. (as outlined in Genomind Assay Report)

Clinically significant variations
Gene	Result	Clinical Factors	Relevant therapies
SLC6A4	L(A)/S	Associated with poor response, slow response, and adverse events with SSRI medications test	Caution with: SSRIs
5HT2C	C/C	Associated with increased incidence of weight gain and metabolic syndrome with atypical antipsychotics	Caution with: atypical antipsychotics Therapeutic options: myo-inositol
CACNA1C	G/A	Common variations shows very modest association to schizophrenia and bipolar disorder, but is not diagnostic for either disorder and is also observed in individuals without those disorders	Therapeutic options: mood stabilizers, atypical antipsychotics, omega-3 fatty acids
MTHFR	C/T	Patients with the T allele have reduced enzyme activity resulting in reduced conversion of folic acid/folate to methylfolate. Methylfolate is a precursor to serotonin, norepinephrine, and dopamine synthesis	Therapeutic options: l-methylfolate
CYP2D6	Poor metabolizer (PM) [low activity] *4/*4	Increased risk of elevated serum levels, drug interactions, and reduced production of active moieties	Use increased caution when prescribing substrates in patients who are poor or intermediate metabolizers and, if clinical response and/or blood levels warrant, a dose adjustment may be considered